High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Title:
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Author:
Majolino, Ignazio Ladetto, Marco Locasciulli, Anna Drandi, Daniela Benedetti, Fabio Gallamini, Andrea Chisesi, Teodoro De Blasio, Angelo Boccadoro, Mario Tarella, Corrado